AGL 40.21 Increased By ▲ 0.18 (0.45%)
AIRLINK 127.64 Decreased By ▼ -0.06 (-0.05%)
BOP 6.67 Increased By ▲ 0.06 (0.91%)
CNERGY 4.45 Decreased By ▼ -0.15 (-3.26%)
DCL 8.73 Decreased By ▼ -0.06 (-0.68%)
DFML 41.16 Decreased By ▼ -0.42 (-1.01%)
DGKC 86.11 Increased By ▲ 0.32 (0.37%)
FCCL 32.56 Increased By ▲ 0.07 (0.22%)
FFBL 64.38 Increased By ▲ 0.35 (0.55%)
FFL 11.61 Increased By ▲ 1.06 (10.05%)
HUBC 112.46 Increased By ▲ 1.69 (1.53%)
HUMNL 14.81 Decreased By ▼ -0.26 (-1.73%)
KEL 5.04 Increased By ▲ 0.16 (3.28%)
KOSM 7.36 Decreased By ▼ -0.09 (-1.21%)
MLCF 40.33 Decreased By ▼ -0.19 (-0.47%)
NBP 61.08 Increased By ▲ 0.03 (0.05%)
OGDC 194.18 Decreased By ▼ -0.69 (-0.35%)
PAEL 26.91 Decreased By ▼ -0.60 (-2.18%)
PIBTL 7.28 Decreased By ▼ -0.53 (-6.79%)
PPL 152.68 Increased By ▲ 0.15 (0.1%)
PRL 26.22 Decreased By ▼ -0.36 (-1.35%)
PTC 16.14 Decreased By ▼ -0.12 (-0.74%)
SEARL 85.70 Increased By ▲ 1.56 (1.85%)
TELE 7.67 Decreased By ▼ -0.29 (-3.64%)
TOMCL 36.47 Decreased By ▼ -0.13 (-0.36%)
TPLP 8.79 Increased By ▲ 0.13 (1.5%)
TREET 16.84 Decreased By ▼ -0.82 (-4.64%)
TRG 62.74 Increased By ▲ 4.12 (7.03%)
UNITY 28.20 Increased By ▲ 1.34 (4.99%)
WTL 1.34 Decreased By ▼ -0.04 (-2.9%)
BR100 10,086 Increased By 85.5 (0.85%)
BR30 31,170 Increased By 168.1 (0.54%)
KSE100 94,764 Increased By 571.8 (0.61%)
KSE30 29,410 Increased By 209 (0.72%)

The Royal College of Physicians of Edinburgh (RCPE) is organising a Symposium (teleconference) on Haematology on Friday November 4th, 2011 and the Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC) is making arrangements to have this teleconference live in the hospital.
Significant advances have occurred in all aspects of haematology in the last decade. These include a new era for oral anticoagulation therapy with the emergence of the first oral anticoagulants since warfarin over 50 years ago. These agents are likely to change the management of many patients at risk of thrombosis. Meanwhile, improved understanding of disease pathophysiology is being translated into novel targeted therapies for patients with haematological malignancies. These developments, however, occur on the background of an increasingly elderly population and incidence of haematological malignancies. All these exciting new agents are expensive and occur at a time of increasing demand and greater patient complexity.
According to the hospital's spokesman, this one day programme will review the challenges presented by the use of these novel therapeutic approaches and the changing patient demographics; both are likely to have a major impact in primary and secondary care. The emphasis of this event is to provide a frame of reference for the practical application of these new developments.
Presentations are from dynamic and engaging speakers, experts in their field. The programme will be of interest not only to trainees, specialist nurses, and haematologists but those working in primary and secondary care since these new developments are likely to have wide ranging impacts across many areas of patient care. Audience will have the opportunity to participate in the question and answer sessions with the panelists.

Copyright Business Recorder, 2011

Comments

Comments are closed.